Clinical Trial Detail

NCT ID NCT02322281
Title TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Clovis Oncology, Inc.
Indications

non-small cell lung carcinoma

Therapies

Pemetrexed

Gemcitabine

Paclitaxel

Docetaxel

Rociletinib

Age Groups: adult

Additional content available in CKB BOOST